UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $251.34, but opened at $235.10. UCB shares last traded at $235.10, with a volume of 1 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on UCBJF. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, UCB currently has an average rating of “Moderate Buy”.

UCB Price Performance

The firm’s fifty day simple moving average is $268.04 and its 200-day simple moving average is $287.56. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.